Neisseria gonorrhoeae sequence typing for antimicrobial resistance, a novel antimicrobial resistance multilocus typing scheme for tracking global dissemination of N. Gonorrhoeae strains by Demczuk, W. et al.
Neisseria gonorrhoeae Sequence Typing
for Antimicrobial Resistance, a Novel
Antimicrobial Resistance Multilocus
Typing Scheme for Tracking Global
Dissemination of N. gonorrhoeae Strains
W. Demczuk,a S. Sidhu,a M. Unemo,b D. M. Whiley,c V. G. Allen,d J. R. Dillon,e
M. Cole,f C. Seah,d E. Trembizki,c D. L. Trees,g E. N. Kersh,g A. J. Abrams,g
H. J. C. de Vries,h,i,j A. P. van Dam,k,l I. Medina,a A. Bharat,a M. R. Mulvey,a
G. Van Domselaar,a I. Martina
Public Health Agency of Canada, National Microbiology Laboratory, Winnipeg, MB, Canadaa; WHO
Collaborating Centre for Gonorrhoea and Other STIs, Örebro University Hospital, Örebro, Swedenb; The
University of Queensland, Centre for Clinical Research, Brisbane, Australiac; Public Health Ontario Laboratories,
Toronto, Ontario, Canadad; Department of Microbiology and Immunology, University of Saskatchewan,
Saskatoon, Saskatchewan, Canadae; Public Health England, London, United Kingdomf; Division of STD
Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, USAg; STI Outpatient Clinic,
Department of Infectious Diseases, Public Health Service Amsterdam, Amsterdam, the Netherlandsh;
Department of Dermatology, Academic Medical Center, University of Amsterdam, Amsterdam, the
Netherlandsi; Center for Infection and Immunity Amsterdam, Academic Medical Center, University of
Amsterdam, Amsterdam, the Netherlandsj; Public Health Laboratory, Public Health Service Amsterdam,
Amsterdam, the Netherlandsk; Department of Medical Microbiology, OLVG General Hospital, Amsterdam, the
Netherlandsl
ABSTRACT A curated Web-based user-friendly sequence typing tool based on anti-
microbial resistance determinants in Neisseria gonorrhoeae was developed and is
publicly accessible (https://ngstar.canada.ca). The N. gonorrhoeae Sequence Typing
for Antimicrobial Resistance (NG-STAR) molecular typing scheme uses the DNA se-
quences of 7 genes (penA, mtrR, porB, ponA, gyrA, parC, and 23S rRNA) associated
with resistance to -lactam antimicrobials, macrolides, or ﬂuoroquinolones. NG-STAR
uses the entire penA sequence, combining the historical nomenclature for penA
types I to XXXVIII with novel nucleotide sequence designations; the full mtrR se-
quence and a portion of its promoter region; portions of ponA, porB, gyrA, and parC;
and 23S rRNA sequences. NG-STAR grouped 768 isolates into 139 sequence types
(STs) (n  660) consisting of 29 clonal complexes (CCs) having a maximum of a
single-locus variation, and 76 NG-STAR STs (n  109) were identiﬁed as unrelated
singletons. NG-STAR had a high Simpson’s diversity index value of 96.5% (95% conﬁ-
dence interval [CI]  0.959 to 0.969). The most common STs were NG-STAR ST-90
(n  100; 13.0%), ST-42 and ST-91 (n  45; 5.9%), ST-64 (n  44; 5.72%), and ST-139
(n  42; 5.5%). Decreased susceptibility to azithromycin was associated with NG-
STAR ST-58, ST-61, ST-64, ST-79, ST-91, and ST-139 (n  156; 92.3%); decreased sus-
ceptibility to cephalosporins was associated with NG-STAR ST-90, ST-91, and ST-97
(n  162; 94.2%); and ciproﬂoxacin resistance was associated with NG-STAR ST-26,
ST-90, ST-91, ST-97, ST-150, and ST-158 (n  196; 98.0%). All isolates of NG-STAR ST-
42, ST-43, ST-63, ST-81, and ST-160 (n  106) were susceptible to all four antimicro-
bials. The standardization of nomenclature associated with antimicrobial resistance
determinants through an internationally available database will facilitate the moni-
toring of the global dissemination of antimicrobial-resistant N. gonorrhoeae strains.
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Neisseria gonorrhoeae, the causative agent of gonorrhea, is a global public healthconcern causing an estimated 78 million new cases of gonorrhea among adults
every year (1). N. gonorrhoeae has developed resistance to almost all of the antimicro-
bials previously used for the treatment of gonorrhea, including penicillins, tetracyclines,
and ﬂuoroquinolones (2, 3); the remaining treatment options are now threatened by
the emergence of resistance to third-generation cephalosporins and azithromycin
(4–13).
The genes attributed to cephalosporin, ﬂuoroquinolone, and azithromycin resis-
tances have been well characterized (3); however, the lack of an internationally stan-
dardized classiﬁcation nomenclature makes it difﬁcult to compare the mutations
implicated in resistance in individual gonococcal isolates. Agreement on the nomenclature
of antimicrobial resistance (AMR) determinants through an internationally available,
curated, user-friendly database containing sequence information and appropriate mi-
crobiological, genetic, clinical, and epidemiological data is of the utmost importance
(14–16).
Variations in nucleotide sequences of penA (encoding penicillin binding protein 2
[PBP2]) are associated with resistance to cephalosporin and penicillin (2, 14, 17) and
include the acquisition of penA mosaic sequences through recombination with penA
genes from other Neisseria species as well as various other amino acid substitutions.
Historically, the nomenclature used for the penA gene has been the assignment of PBP2
types I to XXXVIII based on amino acid substitution proﬁles at 82 selected amino acid
positions (9) rather than nucleotide sequence differences. N. gonorrhoeae Sequence
Typing for Antimicrobial Resistance (NG-STAR) uses this historical amino-acid-based
nomenclature as a basis for allele numbering while creating a more convenient and
easier-to-maintain naming system. Mutations in the promoter and/or coding region of
the mtrR repressor may result in the overexpression of the MtrCDE efﬂux pump. Known
mtrR mutations associated with resistance to macrolides, cephalosporins, tetracycline,
and penicillin include a 35A deletion in the promoter sequence, an A39T or G45D
mutation in the coding region, or the presence of N. meningitidis-like sequences (2, 14,
18–21). Variations in porB1b, encoding an outer membrane porin protein, causing
amino acid substitutions at G120 and A121 (or G101 and A102, respectively, if the
19-amino-acid signal sequence is not included), also historically referred to as the penB
resistance determinant, can decrease membrane permeability and the uptake of ceph-
alosporins, tetracycline, and penicillin (2, 14, 22–25). The L421P variation caused by a
mutation in ponA (PBP1) is involved in chromosomally mediated resistance to penicil-
lins. The L421P mutation is present in many circulating N. gonorrhoeae strains, including
those with elevated cephalosporin MICs; however, this mutation has not caused
signiﬁcantly increased cephalosporin MICs in transformation experiments (2, 3, 26).
Fluoroquinolone resistance in N. gonorrhoeae is conferred via variations in gyrA (subunit
A of DNA gyrase) that induce changes at amino acid positions S91 and/or D95 and
those in parC (topoisomerase IV subunit C) that alter amino acids at positions D86, S87,
and/or S88 (2, 3, 27). Point mutations in the peptidyl-transferase loop region in domain
V of 23S rRNA confer resistance to azithromycin (2, 3, 28, 29). By convention, the
locations of the 23S rRNA nucleotide mutations are based on the Escherichia coli
coordinates of A2059G and C2611T, which correspond to A2045G and C2597T, respec-
tively, of N. gonorrhoeae NCCP11945 (GenBank accession number NC_011035.1). The N.
gonorrhoeae genome carries 4 gene alleles encoding 23S rRNA, and although the
number of mutated alleles has been correlated with increasing resistance (28), a strain
with one mutated allele can rapidly acquire mutations in all 4 alleles (29).
In the present study, a novel sequence-based molecular antimicrobial resistance
typing scheme and Web-based analysis software, NG-STAR, were developed through an
international collaboration. NG-STAR addresses the complex nomenclature applied to
variations in multiple antimicrobial resistance genes of N. gonorrhoeae and can be used
to monitor the global dissemination of antimicrobial-resistant N. gonorrhoeae strains.
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NG-STAR currently contains 215 sequence types (STs) corresponding to unique
allelic proﬁles consisting of concatenated allele identiﬁcations for penA, mtrR, porB,
ponA, gyrA, parC, and 23S rRNA loci.
penA alleles. NG-STAR currently includes 49 penA types, including 21 historical and
28 novel amino acid proﬁles, with 80 penA gene alleles (Table 1). The most allelic
diversity was seen for penA type II (penA alleles 2.001 to 2.006), penA type XXII (alleles
22.001 to 22.006), and penA type XXXIV (alleles 34.001 to 34.006). There were 16 mosaic
(n 228) and 32 nonmosaic (n 541) penA types among the 769 isolates analyzed. The
most common mosaic type was penA type XXXIV (n  197), with 79.7% (n  157) of
isolates carrying penA allele 34.001, and the most common nonmosaic type was penA
type II (n  169), where allele 2.001 accounted for 88% of the isolates (n  149).
mtrR alleles. There are currently 51 mtrR allele types in the database (Table 2), with
6 alleles having the 35A deletion in the promoter region, 19 having either the A39T
or G45D substitution in MtrR, 6 having an N. meningitidis-like mosaic sequence, and 20
alleles having none of these mutations. The mtrR1 allele, which has 35A promoter
deletion only, accounted for 43.2% (n  332) of the isolates included in this study.
porB alleles. There are currently 16 porB allele types in the database, 14 of which are
porB1b and 2 of which correspond to porB1a sequences. Of the porB1b sequences, 13
have the corresponding G120 and/or A121 amino acid substitution in PorB1b. The
porB11 allele (with G120K/A121N) was most common among the isolates tested,
representing 30.8% (n  237) of the porB alleles, followed by porB1 (wild type at
G120/A121), with 16.8% (n  129), and porB8 (G120K/A121D), with 16.6% (n  128).
ponA alleles. Six ponA alleles are currently present in NG-STAR, four of which have
the PBP1 L421P substitution present. The ponA1 allele (L421P) was predominant among
the strains tested, representing 52.8% (n  406) of the isolates.
gyrA alleles. There are 10 gyrA alleles listed in NG-STAR so far, 5 of which possess
a S91 and/or a D95 substitution in GyrA. Among the strains analyzed, 47.7% (n  367)
harbored gyrA0 (wild type with no mutations), and 39.5% (n  304) harbored gyrA1
(S91F/D95G).
parC alleles. NG-STAR currently includes 21 parC alleles, and 13 have substitutions
at amino acid positions D86, S87, and/or S88 in ParC. The most predominant allele
among the strains in this study was parC3 (S87R), in 37.3% (n  287) of the isolates,
followed by parC0 and parC1 (both wild type at D86, S87, and S88), in 16.8% (n  129)
and 15.0% (n  115) of the strains, respectively.
23S rRNA alleles. There are currently 10 23S rRNA alleles in the NG-STAR database,
with 2 having a C2611T mutation that is associated with low to moderate resistance
(MIC  2 to 32 g/ml depending upon the number of alleles mutated) and 1 having
an A2059G mutation that causes high-level resistance (MIC  256 g/ml with more
than 2 mutated alleles). The 23S rRNA wild-type allele 23S-0 accounted for 64.6% (n 
497), 23S-2 (with C2611T) accounted for 21.7% (n  167), and 23S-1 (A2059G) ac-
counted for 1.2% (n  9) of the isolates tested.
Sequence types. Analysis of 768 N. gonorrhoeae isolates identiﬁed 215 NG-STAR STs
(see Table S1 in the supplemental material). goeBURST analysis of the NG-STAR allelic
proﬁles (Fig. S1) grouped 660 isolates into 28 clonal complexes (CCs) of 215 NG-STAR
STs having single-locus variations, and 109 isolates were identiﬁed as 76 singleton
NG-STAR STs having 2 locus variations, which generated a Simpson’s diversity index
value of 96.5% (95% conﬁdence interval [CI]  0.959 to 0.969). Sixteen NG-STAR STs
were composed of 10 or more isolates (Table S2) (n  439; 57.1%), and 134 NG-STAR
STs consisted of a single isolate (n  134; 17.4%). Multilocus sequence typing (MLST)
analysis produced 86 MLST STs, with 435 isolates grouping into 6 CCs, and 39 MLST STs
were singletons (n  222), producing a Simpson’s diversity index value of 86.6% (95%
CI  0.846 to 0.886). Analysis by N. gonorrhoeae multiantigen sequence typing (NG-
MAST) produced 209 NG-MAST STs, grouping 537 isolates into 20 CCs and 181 isolates
into 103 singleton NG-MAST STs, resulting in a Simpson’s diversity index value of 97.0%
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(95% CI  0.964 to 0.975). The congruence of the three typing methods was deter-
mined with the adjusted Wallace coefﬁcient (AW), with AWNG-STAR¡MLST equaling 0.780
(95% CI  0.712 to 0.848) and AWNG-STAR¡NG-MAST equaling 0.368 (95% CI  0.321 to
0.416), meaning that isolates grouped by NG-STAR have a 78% chance of grouping by
MLST and a 37% chance of grouping by NG-MAST.
The most common NG-STAR ST was ST-90 (n  100; 13.0%), followed by ST-42 and
ST-91 (each n  45; 5.9%), ST-64 (n  44; 5.72%), and ST-139 (n  42; 5.5%). NG-STAR
ST-90 was also the most diverse ST (see Table S2 in the supplemental material) and
consisted of 7 MLST and 24 NG-MAST STs (n  96). NG-STAR ST-91 had 2 MLST and 7
NG-MAST STs (n  42), NG-STAR ST-42 had 1 MLST and 2 NG-MAST STs (n  45),
NG-STAR ST-64 had 3 MLST and 2 NG-MAST STs (n  42), and ST-139 had 1 MLST and
10 NG-MAST STs (n  42).
Some NG-STAR STs were correlated geographically with Brazilian isolates grouping
into 8 NG-STAR STs, 5 of which were unique to Brazil (n  5), whereas 22 NG-STAR STs
were observed among isolates from the Netherlands having 15 unique NG-STAR STs
(n  23), 20 NG-STAR STs (n  31) were unique to the United States out of a total
of 28, and all Chinese isolates (n  10) were associated with 7 unique NG-STAR STs
(Table 3).
NG-STAR STs, allelic proﬁles, and antimicrobial MICs for a selection of internationally
available reference strains are presented in Table 4, and the characteristics of prevalent
NG-STAR STs are presented in Table 5. Speciﬁc NG-STAR STs were associated with
characteristic antimicrobial resistance levels. Among the common NG-STAR STs con-
sisting of 10 or more isolates, 92.3% of isolates with NG-STAR ST-61, ST-64, ST-79, ST-91,
or ST-139 (n  156) had an azithromycin MIC of 2.0 g/ml, compared to 6.2% (n 
17) of isolates of other prevalent STs (P  0.001) (Table 5). Similarly, 86.1% (n  142)
of NG-STAR ST-90, ST-91, or ST-97 isolates had a ceftriaxone MIC of 0.06 g/ml (P 
0.001), and 92.1% (n  165) had a ceﬁxime MIC of 0.125 g/ml (P  0.001).
Concurrently reduced susceptibilities to azithromycin and cephalosporins were present
among NG-STAR ST-91 strains, where 86.7% (n  39) had an azithromycin MIC of 2.0
g/ml and a ceftriaxone MIC of 0.06 g/ml (P  0.001). NG-STAR ST-26, ST-90, ST-91,
ST-97, ST-150, and ST-158 were associated with ciproﬂoxacin resistance, with an MIC of
1.0 g/ml (98.0%; n  196; P  0.001), whereas NG-STAR ST-42, ST-43, ST-63, ST-81,
and ST-160 (n  106) were susceptible to all four antimicrobials. Minimum spanning
tree analysis using goeBURST further illustrated the association of NG-STAR STs with
antimicrobial susceptibilities (Fig. 1). NG-STAR STs with reduced susceptibilities to
ciproﬂoxacin (Fig. 1A), ceftriaxone (Fig. 1C), and ceﬁxime (Fig. 1D) clustered together,
and highly susceptible NG-STAR STs clustered oppositely in the minimum spanning
tree, while those with intermediate MIC ranges were located in between. This pattern
was not as evident for azithromycin susceptibility, where clusters of resistant NG-STAR
STs were scattered throughout the tree (Fig. 1B).
Speciﬁc NG-STAR alleles were also associated with levels of resistance. Isolates with
the 23S rRNA allele 23S-1 (with an A2059T mutation) were the only isolates that also
had azithromycin MICs of 256 g/ml (n  8). Allele 23S-2 with a C2611T mutation as
the sole known azithromycin resistance determinant (not having an mtrR 35A dele-
tion or A39T or G45D mutation, an N. meningitidis-like promoter, or a 23S rRNA A2059T
mutation) was identiﬁed in 33 of 34 azithromycin-resistant isolates, whereas only 2 of
the 70 isolates with no known determinants were resistant (P  0.001). The mtrR27,
mtrR28, mtrR30, mtrR39, mtrR44, and mtrR46 alleles contain an N. meningitidis-like mtrR
promoter sequence, which was the sole determinant in 17 azithromycin-resistant
isolates and only 2 susceptible isolates (P  0.001). Similarly, 24 of 27 isolates with only
the gyrA S91 and D95 ciproﬂoxacin resistance determinants, corresponding to the
gyrA1 and gyrA7 alleles, respectively, were ciproﬂoxacin resistant (MIC  1 g/ml),
whereas only 4 of 399 isolates with no resistance determinants (both wild-type gyrA
S91/D95 and wild type parC D86/S87/S88) were resistant (P  0.001).
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The emergence of extensively antimicrobial-resistant gonococcal infections to-
gether with the increased use of nucleic acid ampliﬁcation tests for diagnosis have
highlighted the need for rapid and standardized molecular-based methods to enhance
surveillance of this disease. NG-STAR is a novel molecular typing scheme developed to
facilitate the standardization and organization of the nomenclature of N. gonorrhoeae
loci commonly associated with resistance to macrolides, cephalosporins, penicillins,
TABLE 2Molecular antimicrobial resistance determinants present in NG-STAR mtrR, porB, ponA, gyrA, parC, and 23S rRNA alleles
Allele
Resistance determinant(s) for NG-STAR allelea
mtrR porB ponA gyrA parC 23S rRNA
0 WT WT WT WT WT WT
1 35A deletion None L421P S91F, D95G None A2059G
2 35A deletion A121D WT S91F, D95N None C2611T
3 None A121S L421P S91Y S87R None
4 None G120D L421P None D86N None
5 None G120D, A121D L421P S91F S87R, S88P None
6 None G120D, A121N None None None
7 None G120K, A121D S91F, D95A None C2611T
8 None G120K, A121D WT S87N None
9 A39T G120R, A121D S91F D86N None
10 A39T G120K, A121D None None None
11 A39T G120K, A121N D86N, S88P
12 None G120K, A121G S87I
13 None porB1a S87N
14 None porB1a S87R
15 None A120K, A121Vb S87N
16 35A deletion G120N S87R
17 None None
18 None D86N









28 N. meningitidis -like
29 None







37 35A deletion, A39T,G45D
38 A39T





44 N. meningitidis -like
45 None






aWT signiﬁes the allelic wild-type DNA sequence lacking known antimicrobial resistance molecular markers.
bA 2-codon deletion results in a 2-amino-acid frameshift.
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and ﬂuoroquinolones. NG-STAR is intended as an adjunct typing scheme to inte-
grate antimicrobial resistance information with existing successful molecular epi-
demiological typing schemes such as MLST and NG-MAST. Although AMR proﬁles
have been indirectly associated with particular NG-MAST genotypes, several problems
exist, including the fact that AMR associations with NG-MAST genotypes are not fully
deﬁnitive, rare or infrequent types may have little associated interpretative data
available, and the approach requires continual data updating (16). The association of
AMR and NG-MAST genotypes may also differ regionally, and it is important for each
region to test the hypothesis that NG-MAST genotypes are predictive of AMR (30).
Furthermore, susceptibility of N. gonorrhoeae to third-generation cephalosporins has
been shown to be associated with speciﬁc combined penA-mtrR-porB mutation pat-
terns (31). NG-STAR has the ﬂexibility to directly associate resistance-determining
mutations of the major genes with AMR proﬁles and to capture novel resistance
mutations within these genes.
NG-STAR was validated with a wide selection of reference strains and internationally
collected clinical isolates and produced a desirable high Simpson’s diversity index value
(32) comparable to that of NG-MAST and better than that of MLST. Speciﬁc NG-STAR STs
are deﬁned by mutations within antimicrobial resistance-determining alleles; therefore,
each distinctive allelic proﬁle is directly associated with a characteristic antimicrobial
resistance proﬁle. Each allele number relates to speciﬁc molecular antimicrobial resis-
tance determinants, and consequently, each allelic proﬁle will represent a composite of
such determinants, creating an NG-STAR ST that should have a characteristic antimi-
crobial resistance phenotype. NG-STAR ST-90, ST-91, and ST-97 isolates possess mosaic
TABLE 3 Geographical distribution of NG-STAR sequence types
NG-STAR sequence type(s)
(total no. of isolates)
No. of isolates
Brazil Canada China Netherlands USA
26 (15) 14 1
46 (2) 1 1
56 (2) 1 1
57 (8) 7 1
58 (10) 9 1
63 (16) 9 6 1
64 (44) 34 4 6
90 (100) 1 59 5 35
91 (44) 2 40 2
127 (3) 2 1
139 (42) 36 3 3
158 (10) 6 4
209 (1), 210 (1), 214 (1),
216 (1), 217 (1)
5
199 (1), 200 (2), 201 (1),
202 (1), 203 (2), 204 (1),
221 (2)
10
177 (2), 178 (2), 179 (1),
180 (2), 181 (1), 182 (3),
183 (1), 184 (1), 185 (3),
186 (1), 187 (1), 188 (1),
189 (1), 190 (2), 191 (1)
23
192 (1), 193 (6), 194 (1),
195 (1), 196 (4), 197 (1),
198 (3), 205 (1), 206 (1),
207 (1), 208 (1), 211 (2),
212 (1), 213 (1), 215 (1),
218 (1), 219 (1), 220 (1),
222 (1), 223 (1)
31
Other (382)a 382
Totalb 9 600 10 47 81
aIncluding 138 sequence types and a total of 382 isolates.
bExcludes 21 NCBI reference strains.
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penA type XXXIV and porB mutations that cause substitutions in amino acids G120 and
A121, and these STs exhibit the expected reduced susceptibility to extended-spectrum
cephalosporins (3, 33, 34). Similarly reduced cephalosporin susceptibilities were also
observed among NG-STAR STs with nonmosaic penA alleles with an A501V substitution,
such as penA 43.001, 43.002, and 13.001. Nonmosaic penA type IX, XIII, XVII, or XVIII with
combinations of the A501V, P551S, G542S, and/or P551S/L mutation has been shown
to be associated with N. gonorrhoeae isolates with ceﬁxime and ceftriaxone MICs of
0.03 g/ml (31, 35). In addition to the cephalosporin resistance determinants, NG-
STAR ST-91 also had 23S rRNA allele 23S-2 with a C2611T point mutation, which confers
concurrent resistance to macrolides. High-level azithromycin resistance (MIC  256
g/ml) is associated with NG-STAR ST-30, ST-36, ST-69, ST-192, ST-202, ST-223, and
ST-225, all of which possess the 23S rRNA A2059G mutation of allele 23S-1. Previous
molecular studies have shown that these isolates possessed the A2059G mutation in all
4 alleles (36). Although more than a single mutated 23S rRNA gene in the genome is
required to confer elevated azithromycin MICs (28, 36), the acquisition of a single
mutated allele facilitates the rapid acquisition of a full complement of mutated alleles
under selective pressures (3, 29); therefore, the presence of a single mutation may be
considered a precursor to full resistance, especially if inappropriate treatment adds to
this selective pressure. It is for this reason that NG-STAR records the presence of a
mutation, even if present in a single allele, as being sufﬁcient to identify the potential
for full azithromycin resistance and to recommend an alternative treatment. Azithromycin-
resistant STs did not cluster to the same extent as those with decreased susceptibility
to other antimicrobials in the minimum spanning tree (Fig. 1B), potentially reﬂecting
the more sporadic, nonclonal nature of the acquisition of azithromycin resistance
among many N. gonorrhoeae strains (3, 29, 34, 36), although some subsequent clonal

















































FIG 1 Antimicrobial resistance and genetic relatedness of 768 Neisseria gonorrhoeae isolates determined by goeBURST minimum
spanning tree analysis of NG-STAR allelic proﬁles of seven antimicrobial resistance-related genes. Colored nodes indicate MICs of
ciproﬂoxacin, azithromycin, ceftriaxone, and ceﬁxime. The size of a node is proportional to the number of isolates, and branches are not
to scale.
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A Web-based user-friendly typing tool based on the well-characterized antimicrobial
resistance genes of N. gonorrhoeae was developed, where nucleotide sequences of
penA, mtrR, porB, ponA, gyrA, parC, and 23S rRNA may be queried against curated allelic
libraries employing a standardized nomenclature. Although NG-STAR provides a satis-
factory discriminatory molecular typing scheme for N. gonorrhoeae, it would be more
useful in combination with other epidemiological typing schemes such as NG-MAST to
enhance the molecular surveillance of antimicrobial resistance. Future planned en-
hancements of NG-STAR include interrogation of whole-genome sequence data and
improved analytical functionality such as built-in sequence alignment and protein
translation tools and bulk querying mechanisms. NG-STAR will enable public health
practitioners and researchers around the world to communicate in a common “molec-
ular language” to facilitate improved responses and monitoring of emerging drug-
resistant clones of N. gonorrhoeae and to provide an enhanced understanding of the
dissemination, transmission, and dynamics of gonorrhea, which will inform public
health interventions and reduce the burden of this disease.
MATERIALS AND METHODS
N. gonorrhoeae isolates and antimicrobial susceptibility testing. This study examined 768
N. gonorrhoeae isolates, which included 600 isolates from Canada, 47 from the Netherlands, 31 from
the United States, 10 from China, and 9 from Brazil. Additional international reference strains WHO-F,
WHO-G, WHO-K, WHO-L, WHO-M, WHO-N, WHO-O, WHO-P, WHO-U, WHO-V, WHO-W, WHO-X,
WHO-Y, and WHO-Z (38) and strains ATCC 49226, NCCP11945 (GenBank accession number
NC_011035.1), FA1090 (accession number NC_002946.2), MS11 (accession number NC_022240.1), FA19
(accession number NZ_CP012026.1), FA6140 (accession number NZ_CP012027.1), and 35/02 (accession
number NZ_CP012028.1) from the NCBI were also included. Fifty genomes downloaded from the CDC
Neisseria gonorrhoeae Antimicrobial Resistance Bank (available at http://www.cdc.gov/drugresistance/
resistance-bank/currently-available.html [accessed December 2016]) were included to provide a broader
range of strains. The WHO and CDC Neisseria gonorrhoeae Antimicrobial Resistance Bank strains are
representative of the known antimicrobial resistance determinants for N. gonorrhoeae.
Susceptibilities to azithromycin, ciproﬂoxacin, ceftriaxone, and ceﬁxime (Sigma-Aldrich Canada Ltd.,
Oakville, Ontario, Canada) were determined by using the agar dilution method and quality control strains
as previously described (39, 40).
NG-MAST, MLST, and NG-STAR typing. NG-MAST, MLST, and NG-STAR sequence typing was
performed by using gene sequences extracted in silico from whole-genome sequencing (WGS) data and
submitted to the NG-MAST (http://www.ng-mast.net/), Neisseria MLST (http://pubmlst.org/neisseria/),
and NG-STAR (https://ngstar.canada.ca) websites to determine the respective STs. The relatedness of
allelic proﬁles was visualized by using PHYLOViZ 2.0 (41, 42) to produce a full goeBURST minimum
spanning tree. MLST and NG-STAR CCs were deﬁned by a single-locus variation in allelic proﬁles from a
founding ST, while an NG-MAST CC was determined by 5 or more single-nucleotide polymorphisms of
concatenated and aligned porB and tbpB sequences.
NG-STAR software platform. The NG-STAR analysis platform was written in Perl with the Perl
Catalyst Model-View-Controller (MVC) framework (http://www.catalystframework.org/). It uses the
MariaDB database and Apache Web server software on main and backup servers. The system is available
to the research community as a virtual machine image running the CentOS 7 operating system. The
software is released under the Apache 2.0 open-source license (available at https://github.com/phac-
nml/ngstar). The NG-STAR Web service is publicly available (https://ngstar.canada.ca).
NG-STAR takes the full set of user-submitted locus sequences (trimmed or untrimmed) and ﬁrst looks
for exact matches by using SQL queries. If exact matches are found for all loci, NG-STAR returns the allele
type and corresponding NG-STAR type (sequence type) if it exists. If the allele type combination is not
associated with an NG-STAR type, the system will report the allele types and give an option to submit
the novel allele type combination for curation and possible inclusion in the NG-STAR allele schema.
Submitted sequences without exact matches in the schema are aligned against its corresponding set of
alleles by using nucleotide-level BLAST (43); high-scoring segment pairs above a similarity of 90% and
any match length are reported as a partial match. If one or more of the submitted sequences have partial
matches, the user is given an option to submit the sequence for curation, although the system will not
report a sequence type. Novel alleles (full length) and proﬁles may be submitted for manual curation
through a curator notiﬁcation functionality, where the submitter provides the DNA sequence; trace ﬁle;
contact information (e-mail); and, ideally, additional background information such as isolation date,
clinical source, country of origin, and antimicrobial MICs.
NG-STAR loci. The DNA sequences of 7 genes commonly associated with resistance to -lactam
antimicrobials (e.g., cephalosporins and penicillins), macrolides, or ﬂuoroquinolones (14) were used, including
penA, mtrR, porB, ponA, gyrA, parC, and 23S rRNA. Primers recommended for PCR and conventional Sanger
sequencing and amplicon sizes and fragment sizes used for typing are listed in Table 6.
NG-STAR uses the historical 82-amino-acid-based penA nomenclature developed by Ohnishi et al. (9)
as a basis for allele numbering. This includes penA types I to XXXVIII (now penA types 1 to 38 in Arabic
numerals) and sequentially adds novel types as they are submitted, beginning with penA type 39 (Table
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1). When a novel amino acid substitution proﬁle is detected, a sequential whole number is assigned to
the allele. Novel whole-gene DNA sequences with synonymous mutations coding for a preexisting penA
type will be indicated by an incremental decimal number. For example, the 12th unique whole-gene DNA
sequence for the historical penA type XXXIV amino acid proﬁle would be assigned allele number 34.012.
For the remainder of the loci, each unique sequence is assigned a sequential allele number. NG-STAR
mtrR alleles include a portion of the promoter starting approximately 66 to 68 bp before the ATG start
codon of the coding region and extending the length of mtrR. To limit a potentially very large number
of alleles of the hypervariable porB gene, a small 60-bp segment is used in NG-STAR that includes the
G120- and A121-encoding region associated with antimicrobial resistance. Although the G120/A121
mutations apply only to porB1b, due to the high level of homology of porB1a sequences, and for
enhanced typing purposes, both genes are included in NG-STAR. NG-STAR uses a 75-bp portion of ponA
spanning amino acid L421; a 264-bp portion of gyrA spanning amino acids S91 and D95; and a 332-bp
portion of parC spanning amino acids D86, S87, and S88. 23S rRNA mutations of interest include A2059G
and/or C2611T (E. coli coordinates, corresponding to A2045G and C2597T, respectively, of N. gonorrhoeae
NCCP11945 [GenBank accession number NC_011035.1]). Of the four 23S rRNA alleles present in the N.
gonorrhoeae genome, only a single 567-nucleotide sequence is analyzed by NG-STAR. If no mutated
alleles are present (wild type), any one of the alleles may be submitted; however, if a mutation is present
in any one of the alleles, the sequence with a mutation is submitted, even if it is in the minority. The
combination of allele numbers for all 7 genes (allelic proﬁle) corresponds to a unique NG-STAR type.
Information for a representative reference strain for each allele and NG-STAR type, such as the level
of antimicrobial resistance and relevant clinical and epidemiological data, is available. Allelic queries with
sequences longer than those stored in the library are automatically trimmed to give an exact allele type
match if present in the database, whereas shorter sequences will return possible allele type matches
(hits), and users are encouraged to submit a longer DNA sequence to accurately identify an allele. An
NG-STAR type is returned only with a complete allelic proﬁle generated from exact allelic matches. Novel
alleles (full-length queries containing mismatches) and proﬁles may be submitted through curator
notiﬁcation functionality, where the submitter provides the DNA sequence(s); contact information
(e-mail); and, ideally, additional background information such as isolation date, clinical source, country
of origin, epidemiological background information, and antimicrobial MICs. Curator comments for each
allele and NG-STAR type will be presented, which may include characteristic mutations or other items of
interest for that allele.
Statistical comparisons and calculations. The measure of association was determined by using 2
or Fisher’s exact test using OpenEpi version 3.01 (44). Two-tailed differences with P values of 0.05 at a
95% CI were considered statistically signiﬁcant. The discriminatory power of the NG-STAR, NG-MAST, and
MLST schemes was calculated by using Simpson’s diversity index (32, 45), and congruence of the
methods was determined by using the adjusted Wallace coefﬁcient (46) (calculated by using the online
tool available at http://comparingpartitions.info).
TABLE 6 Gene targets and suggested primers utilized in the NG-STAR typing scheme
Target







penA (17) PenA-A1 (forward) CGGGCAATACCTTTATGGTGGAAC 669 1,746–1,752 1,746–1,752
PenA-B1 (reverse) AACCTTCCTGACCTTTGCCGTC
PenA-A2 (forward) AAAACGCCATTACCCGATGGG 581
PenA-B2 (reverse) TAATGCCGCGCACATCCAAAG
PenA-A3 (forward) GCCGTAACCGATATGATCGA 863
PenA-B3 (reverse) CGTTGATACTCGGATTAAGACG
PenA-A4 (forward) AATTGAGCCTGCTGCAATTGGC
mtrR (18) MTR1 (forward) AACAGGCATTCTTATTTCAG 916 698–708 (includes
promoter region)
Gene, 633;
promoter, 251MTR2 (reverse) TTAGAAGAATGCTTTGTGTC
ponA (26) ponA1-f (forward) CGCGGTGCGGAAAACTATATCGAT 1,240 75 2,397
ponA1-r (reverse) AGCCCGGATCGGTTACCATACGTT
porB1b (22) por-NGMAST-F (forward) CAAGAAGACCTCGGCAA 737 30 1,047
por-NGMAST-R (reverse) CCGACAACCACTTGGT
gyrA (27) GYRA-1 (forward) AACCCTGCCCGTCAGCCTTGA 270 264 2,751
GYRA-2 (reverse) GGACGAGCCGTTGACGAGCAG
parC (47) parC F (forward) GTTTCAGACGGCCAAAAGCC 332 332 2,304
parC R (reverse) GGCATAAAATCCACCGTCCCC
23S rRNA (28) gonrRNAF (forward) ACGAATGGCGTAACGATGGCCACA 712 567 2,890
gonrRNAR2 (reverse) TTCGTCCACTCCGGTCCTCTCGTA
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